HDAC-IN-57

• Description :

  HDAC-IN-57 is an orally active inhibitor of histone deacetylases (HDAC), with IC50s of 2.07 nM, 4.71 nM, 2.4 nM and 107 nM for HDAC1, HDAC2, HDAC6, HDAC8, respectively. HDAC-IN-57 can inhibits LSD1, with IC50 of 1.34 μΜ. HDAC-IN-57 induces apoptosis, and has anti-tumor activity[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; HDAC; Histone Demethylase

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/hdac-in-57.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=CC=C(CNC(C2=CC(C3=CC=C(OC)C=C3)=NC=C2)=O)C=C1)NO

• Molecular Formula :

  C21H19N3O4

• Molecular Weight :

  377.39

• References & Citations :

  [1]Duan Y, et al. Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors. Eur J Med Chem. 2023 Jun 5;254:115367.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HDAC1; HDAC2; HDAC6; HDAC8

• CAS Number :

  [2716217-79-5]